JP2021530543A5 - - Google Patents

Info

Publication number
JP2021530543A5
JP2021530543A5 JP2021503571A JP2021503571A JP2021530543A5 JP 2021530543 A5 JP2021530543 A5 JP 2021530543A5 JP 2021503571 A JP2021503571 A JP 2021503571A JP 2021503571 A JP2021503571 A JP 2021503571A JP 2021530543 A5 JP2021530543 A5 JP 2021530543A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
product according
patient
riluzole
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021503571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530543A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/042718 external-priority patent/WO2020023324A1/en
Publication of JP2021530543A publication Critical patent/JP2021530543A/ja
Publication of JP2021530543A5 publication Critical patent/JP2021530543A5/ja
Priority to JP2025026643A priority Critical patent/JP2025093952A/ja
Pending legal-status Critical Current

Links

JP2021503571A 2018-07-22 2019-07-20 アルツハイマー病を処置するためのリルゾールプロドラッグの使用 Pending JP2021530543A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025026643A JP2025093952A (ja) 2018-07-22 2025-02-21 アルツハイマー病を処置するためのリルゾールプロドラッグの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701814P 2018-07-22 2018-07-22
US62/701,814 2018-07-22
PCT/US2019/042718 WO2020023324A1 (en) 2018-07-22 2019-07-20 Use of riluzole prodrugs to treat alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025026643A Division JP2025093952A (ja) 2018-07-22 2025-02-21 アルツハイマー病を処置するためのリルゾールプロドラッグの使用

Publications (2)

Publication Number Publication Date
JP2021530543A JP2021530543A (ja) 2021-11-11
JP2021530543A5 true JP2021530543A5 (cg-RX-API-DMAC7.html) 2022-02-15

Family

ID=69181140

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021503571A Pending JP2021530543A (ja) 2018-07-22 2019-07-20 アルツハイマー病を処置するためのリルゾールプロドラッグの使用
JP2025026643A Pending JP2025093952A (ja) 2018-07-22 2025-02-21 アルツハイマー病を処置するためのリルゾールプロドラッグの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025026643A Pending JP2025093952A (ja) 2018-07-22 2025-02-21 アルツハイマー病を処置するためのリルゾールプロドラッグの使用

Country Status (14)

Country Link
US (1) US12161633B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823616A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021530543A (cg-RX-API-DMAC7.html)
KR (1) KR20210034621A (cg-RX-API-DMAC7.html)
CN (1) CN112469408A (cg-RX-API-DMAC7.html)
AU (1) AU2019310013B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021000768A2 (cg-RX-API-DMAC7.html)
CA (1) CA3107215A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190308A1 (cg-RX-API-DMAC7.html)
IL (1) IL280177B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021000515A (cg-RX-API-DMAC7.html)
PH (1) PH12021550043A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100385YA (cg-RX-API-DMAC7.html)
WO (1) WO2020023324A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299301A (en) * 2020-06-24 2023-02-01 Biohaven Therapeutics Ltd Compositions and methods for the treatment of obsessive compulsive disorder
EP4240308A4 (en) * 2020-10-05 2024-10-30 Icahn School of Medicine at Mount Sinai Riluzole for the treatment of alzheimer's disease
WO2022155564A1 (en) * 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
BR112023016690A2 (pt) * 2021-02-22 2023-11-14 Univ Yale Degradadores bifuncionais direcionados e métodos usando os mesmos
CN114344297B (zh) * 2022-03-01 2024-05-14 暨南大学 利鲁唑在治疗少精症中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001275525B2 (en) * 2000-06-14 2007-04-26 Medarex, Inc. Tripeptide prodrug compounds
EP1814558B1 (en) * 2004-11-01 2010-12-15 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
WO2015089049A1 (en) 2013-12-09 2015-06-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
US10258611B2 (en) * 2014-11-26 2019-04-16 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same
DK3265448T3 (da) * 2015-03-03 2022-03-28 Biohaven Therapeutics Ltd Riluzol-prodrugs og anvendelse deraf
HRP20220237T1 (hr) * 2016-05-20 2022-04-29 Biohaven Therapeutics Ltd. Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka
US12029731B2 (en) * 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
US10751345B2 (en) * 2018-02-21 2020-08-25 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
WO2022155564A1 (en) * 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease

Similar Documents

Publication Publication Date Title
US11957688B2 (en) Combination therapy with apilimod and glutamatergic agents
JP5911929B2 (ja) 特定の癌の治療のためのrdea119/bay869766を含む組み合わせ医薬
JP2021534160A5 (cg-RX-API-DMAC7.html)
IL189546A0 (en) Therapy for the treatment of disease
US20240122945A1 (en) Use of neuroactive steroids for treatment of sexual dysfunction
JP2021502392A5 (cg-RX-API-DMAC7.html)
JP2017511339A5 (cg-RX-API-DMAC7.html)
JP2011525185A5 (cg-RX-API-DMAC7.html)
JP2021152060A (ja) アカンプロセートおよびd−サイクロセリンを使用する組み合わせ療法
EP4494701A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
JP2014512355A5 (cg-RX-API-DMAC7.html)
JP2016507500A5 (cg-RX-API-DMAC7.html)
JP2022502450A5 (cg-RX-API-DMAC7.html)
JP2022169780A5 (cg-RX-API-DMAC7.html)
JP2024542984A5 (cg-RX-API-DMAC7.html)
JP2022546456A5 (cg-RX-API-DMAC7.html)
JP2023553253A5 (cg-RX-API-DMAC7.html)
JP2021514380A5 (ja) 筋障害及び骨障害を処置するための化合物及び組成物
JP2023518640A5 (cg-RX-API-DMAC7.html)
JP2022512158A5 (cg-RX-API-DMAC7.html)
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
JP2021511352A5 (cg-RX-API-DMAC7.html)
JP2021530568A5 (cg-RX-API-DMAC7.html)
JP2008501023A (ja) 小児患者での癌の治療
JP2024518426A5 (cg-RX-API-DMAC7.html)